Outcomes of Semaglutide Use in Achieving Target Body Mass Index Before Renal Transplant in Five End-Stage Renal Disease Patients: A Case Series.

Obesity is a significant barrier to renal transplantation due to associated surgical risks and postoperative complications. This case series presents five cases of obese patients with end-stage renal disease (ESRD) who successfully achieved substantial weight loss using semaglutide, a glucagon-like peptide (GLP) type-1 receptor agonist, thereby becoming eligible for transplantation. Each patient experienced significant weight reduction, ranging from 11.7% to 14.8% of their baseline weight, with minimal side effects. Semaglutide was well-tolerated, and careful monitoring prevented complications such as fluid overload. These cases highlight the potential of semaglutide as an effective and safe adjunct for weight loss in ESRD patients, offering a viable alternative to lifestyle interventions and bariatric surgery. The findings suggest that semaglutide could broaden the pool of eligible transplant candidates and improve patient outcomes by using semaglutide as a weight loss therapy. Further research is warranted to explore its long-term effects on transplant outcomes and to develop guidelines for its use in clinical practice.
Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
(Copyright © 2024, Al-saad et al.)